Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

Atopic dermatitis and vitiligo are very different disease states clinically. How is it that topical ruxolitinib cream shows efficacy in both of them?

Atopic Dermatitis

When we're looking at the use of topical ruxilitinib for atopic dermatitis and for vitiligo, we have to remember it's a Janus kinase inhibitor, and its use for those particular diseases is the ability to decrease the effect of certain cytokines. In the case of atopic dermatitis, which can have a very quick onset of symptoms and of dermatitis, we're targeting interleukin four, interleukin 13, TSLP, so we can see a very quick effect against itching and reducing the dermatitis. In the case of vitiligo, it's an autoimmune disease. We're targeting interferon gamma, il 15, il six by inhibiting the Janus kinase one and Janus kinase two. Autoimmune processes longer, so we expect it to take longer to see a clinical effect. So when you're treating vitiligo, you might see benefit early on in the first month or two, but we have to give it months to really evaluate the efficacy. So it's two different types of diseases and that's what makes the difference. And.